DNA & Genetics Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer CollaborationBy adminFebruary 26, 20260 Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s most advanced immuno-oncology asset, the prostate cancer candidate VIR-5500, through…
DNA & Genetics Astellas Takes Aim at XLMTM Again, Now with MyoAAV Capsid-Based Gene TherapyBy adminJanuary 21, 20260 More than four years after the last of four boys died in a troubled Phase I/II trial of a gene…
